Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's

“Demonstrates how some of the most accomplished and elite scientific gatekeepers may have lied, cheated, squandered trust and endangered lives.”—The Wall Street Journal

For fans of Empire of Pain and Dopesick, an arresting deep dive into how Alzheimer’s disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma.

Nearly seven million Americans live with Alzheimer’s disease, a tragedy that is already projected to grow into a $1 trillion crisis by 2050. While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Charles Piller’s Doctored shows that we’ve quite likely been walking the wrong path to finding a cure all along—led astray by a cabal of self-interested researchers, government accomplices, and corporate greed.

Piller begins with a whistleblower—Vanderbilt professor Matthew Schrag—whose work exposed a massive scandal. Schrag found that a University of Minnesota lab led by a precocious young scientist and a Nobel Prize-rumored director delivered apparently falsified data at the heart of the leading hypothesis about the disease. Piller’s revelations of Schrag’s findings stunned the field and the public.

From there, based on years of investigative reporting, this “seminal account of deceit that will long be remembered” (Katherine Eban, author of Bottle of Lies and Vanity Fair special correspondent) exposes a vast network of deceit and its players, all the way up to the FDA. Piller uncovers evidence that hundreds of important Alzheimer’s research papers are based on false data. In the process, he reveals how even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field’s institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. It is a shocking tale with huge ramifications not only for Alzheimer’s disease, but for scientific research, funding, and oversight at large.